Overview

• The new settlement plan offers creditors the choice to opt in for payments or opt out to retain the right to sue the Sackler family.
• The Sackler family is contributing between $6.5 billion and $7 billion, a $1 billion increase compared to the previous plan rejected by the Supreme Court.
• Purdue Pharma will be dissolved and replaced by a public benefit company focused on addressing the opioid crisis and producing low-cost naloxone.
• The plan allocates $850 million for individual victims, including those addicted to OxyContin and babies born with withdrawal symptoms.
• Creditor voting on the plan is expected to begin in May 2025, with final approval contingent on a U.S. bankruptcy judge’s decision.